Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Olanzapine Stories

2014-03-20 08:29:49

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy TITUSVILLE, N.J., March 20, 2014 /PRNewswire/ -- Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of paliperidone palmitate 3-month formulation, an investigational treatment for symptoms of schizophrenia in adults. "We are...

2013-12-04 23:31:22

http://www.DrugNews.net is the web’s premier source for prescription drug warnings, research, side effects and legal news. Visit the DrugNews Center today. New York, NY (PRWEB) December 04, 2013 The medication safety advocates at DrugNews.net are announcing a new resource center for parents of children who have taken the antipsychotic drug Risperdal. The site will contain the latest research and safety warnings as well as updated legal news from lawsuits alleging side effects*. DrugNews...

2013-10-14 08:25:33

Drug Launches Will Not Offset a Decline in Major-Market Sales Caused By Increasing Generic Competition For Atypical Antipsychotics, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Dainippon Sumitomo Pharma/Sunovion/Takeda Pharmaceutical's atypical antipsychotic Latuda will experience significant uptake in the...

2013-08-22 10:29:47

Prescribing of "atypical" antipsychotic medications to children and young adults with behavioral problems or mood disorders may put them at unnecessary risk for type 2 diabetes, a Vanderbilt University Medical Center study shows. Young people using medications like risperidone, quetiapine, aripiprazol and olanzapine led to a threefold increased risk of developing type 2 diabetes within the first year of taking the drug, according to the study published Aug. 21 in the journal JAMA...

2013-07-18 08:30:18

WASHINGTON, July 18, 2013 /PRNewswire/ -- Leaders from the medical diagnostics, laboratory medicine, and health care fields will convene in Houston, Texas, July 28 - August 1 for the world's largest diagnostics conference and expo where experts from research and industry will exchange insights on research and application advancements. More than 17,000 attendees and an exhibit with more than 625 companies are expected. Selected research being presented includes new tests to detect...

2013-06-28 23:02:51

UNE Professor of Pharmacology Karen Houseknecht has received a four-year, $1.2 million grant from the National Institutes of Health to further study the effects of second-generation antipsychotic (SGA) medications on bone biology. These drugs are increasingly being prescribed off-label to treat a number of other ailments, including attention-deficit/hyperactivity disorder in children. Portland, Maine (PRWEB) June 28, 2013 The U.S. National Institutes of Health (NIH) reports that as...

2013-03-13 10:28:56

A study published this week in PLOS Medicine finds that while antipsychotic medications are associated with small-to-moderate improvements in depressive symptoms in adults, there is little evidence for improvement on measures of quality of life and these medications are linked to adverse events such as weight gain and sedation. The results of the study, conducted by Glen Spielmans of Metropolitan State University in St. Paul, Minnesota and colleagues, have potential implications for the...

2012-11-28 11:18:28

In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications — schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs. In a new study — led by researchers at the University of California, San...

2012-11-28 08:30:58

WOODCLIFF LAKE, N.J., Nov. 28, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for olanzapine and fluoxetine hydrochloride capsules, 3 mg/25 mg (eq base), 6 mg/25 mg (eq base), 6 mg/50 mg (eq base), 12 mg/25 mg (eq base) and 12 mg/50 mg (eq base). Olanzapine and fluoxetine hydrochloride is the...

2012-10-24 07:30:05

INDIANAPOLIS, Oct. 24, 2012 /PRNewswire/ -- Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations. Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets. Third-quarter earnings per share were $1.18 (reported), or $0.79 (non-GAAP, when excluding income from Amylin payment and asset impairment and restructuring charge). Data read-outs provided a better understanding of several potential new...